Join The Community

Summary

The product AROMASIN 10mg, manufactured by Unique Pharma, was independently tested to verify its authenticity and potency. The sample, identified by batch number UN66337, was submitted by the reseller Opitropin.EU and analyzed by Janoshik Analytical, a laboratory specializing in pharmaceutical quality control. The analysis measured the presence of Exemestane, with a concentration of 10.93 mg, exceeding the labeled claim of 10 mg by 9.3%.

The testing process commenced on 12 November 2024, with the sample received on 19 November 2024, and the analysis completed on 20 November 2024. While the results confirm the product is slightly overdosed, it is important to consider that reseller-submitted samples may represent optimal batches and may not fully reflect overall market consistency. Independent third-party testing is essential to validate these findings comprehensively. This report serves as an educational resource to promote harm reduction and informed decision-making.

Detailed Report

Product Overview

Sample Acquisition and Testing

Testing Results

Verification Details

Evaluation of Reseller-Submitted Testing

This analysis confirms that the tested product meets and slightly exceeds its labeled claim, but it is important to acknowledge that the sample was submitted and funded by the reseller Opitropin.EU. Resellers often select high-quality batches for testing, which may not represent the consistency of products available to consumers. Further independent verification across multiple batches is recommended to ensure uniformity across the entire product line.

Conclusion

The analysis confirms that AROMASIN 10mg contains a measured concentration of 10.93 mg, reflecting a slight overdose. This suggests strong quality control for this batch; however, additional testing across different batches is recommended to ensure consistent dosing. This report aims to support educational and harm reduction efforts, allowing consumers to make informed decisions.

Disclaimer

This report is published for educational and harm reduction purposes. Reseller-submitted testing may introduce inherent biases; however, it still provides useful insights when critically assessed alongside third-party independent results. Readers are encouraged to use this information responsibly.